Healthcare / Medical Care FacilitiesBSE
$648.10
+11.60 (+1.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $989.0M · quality 59.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$96.8B
P/E
682.2x
↑EV/EBITDA
24.3x
↑ROE
1.0%
↑Gross Margin
51.1%
↑Debt/Equity
1.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+14.8%
FCF CAGR
-22.5%
FCF margin
2.2%
FCF / Net income
4.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $25.38B · net income $137.6M · FCF $550.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $25.38B | $25.38B | $22.18B | $18.90B | $16.76B |
| Net Income | $137.6M | $137.6M | $444.1M | $481.6M | $293.5M |
| EBITDA | $4.48B | $4.48B | $4.23B | $3.43B | $3.03B |
| EPS | — | — | 3.12 | 3.41 | 2.09 |
| Gross Margin | 51.1% | 51.1% | 52.1% | 51.9% | 52.3% |
| Operating Margin | 8.7% | 8.7% | 7.9% | 8.3% | 10.0% |
| Net Margin | 0.5% | 0.5% | 2.0% | 2.5% | 1.8% |
| Balance Sheet | |||||
| Debt/Equity | 1.30 | 1.30 | 1.99 | 1.54 | 1.05 |
| Current Ratio | 1.12 | 1.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $550.0M | $550.0M | $1.08B | $989.0M | $1.18B |
| Returns | |||||
| ROE | 1.0% | 1.0% | 4.8% | 5.8% | 3.4% |
| Valuation | |||||
| P/E | 682.21 | 682.21 | 169.58 | 107.91 | 130.32 |
| EV/EBITDA | 24.29 | 24.29 | 21.60 | 18.08 | 14.97 |
| P/B | 7.26 | 7.26 | 8.16 | 6.29 | 4.42 |
| Growth & Yield | |||||
| Revenue Growth | 14.4% | 14.4% | 17.4% | 12.8% | — |
| EPS Growth | — | — | -8.5% | 63.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.4%
Start / end P/E
n/dx → n/dx
EPS bridge
3.12 → n/d
Residual
+9.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.